

Journal of Lipid Research

ATP-binding cassette transporters mediate differential glycosphingolipid biosynthesis

--Manuscript Draft--

Manuscript Number:	JLR-D-██████████
Full Title:	ATP-binding cassette transporters mediate differential glycosphingolipid biosynthesis
Short Title:	ABC transporters mediate GSL biosynthesis
Article Type:	Research Article
Keywords:	ABC transporter; glucosylceramide flippase; glycosphingolipid
Corresponding Author:	██████████ ██████████
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	██
Corresponding Author's Secondary Institution:	
First Author:	██████████
First Author Secondary Information:	
Order of Authors:	██████████ ████████████████████ ██████████
Order of Authors Secondary Information:	
Abstract:	<p>The cytosolic-oriented glucosylceramide (GlcCer) synthase is problematic, requiring nascent GlcCer translocation to the luminal Golgi membrane to access GSL anabolic glycosyltransferases. The mechanism by which GlcCer is flipped remains unclear. Using a GlcCer photoprobe, we identified ATP-binding cassette (ABC) transporters ABCA3, ABCB4 and ABCB10 as microsomal GlcCer-binding proteins in DU-145 prostate tumor cells. siRNA knockdown (KD) of these ABC transporters differentially blocked GSL synthesis assessed <i>in toto</i> and via metabolic labelling. KD of ABCA3 reduced acid/neutral GSLs but increased lactosylceramide (LacCer), ABCB4 preferentially reduced neutral GSLs, and ABCB10 reduced both neutral and acidic GSLs. KD of other ABC proteins implicated in GlcCer transport were also investigated. ABCA12 depletion preferentially decreased neutral GSLs. ABCB1 KD preferentially reduced gangliosides, but increased Gb₃. These results infer multiple ABC transporters provide distinct but overlapping GlcCer (and LacCer) pools within the Golgi lumen stacks for anabolism of different GSL series by metabolic channeling. Differential ABC family member usage/redundancy may fine tune GSL biosynthesis according to cell/tissue type. ABC transporters provide a new tool for the regulation of GSL biosynthesis and potential targets to reduce selected GSL species/subsets in GSL dysregulated diseases.</p>
Suggested Reviewers:	██████████ ██████████ ██████████
Opposed Reviewers:	
Additional Information:	

Question	Response
<p>Resubmission Is this manuscript a resubmission? Please select "Yes" if you are resubmitting a rejected manuscript, or if you have exceeded the 180 day limit to revise your original manuscript and are resubmitting.</p>	No
<p>Dual Publication Have the results/data/figures in this manuscript been published or are they under consideration for publication elsewhere?</p>	No, the results/data/figures in this manuscript have not been published elsewhere, nor are they under consideration (from you or one of your Contributing Authors) by another publisher.
<p>Companion Manuscript Is this manuscript a companion paper? If this is the first paper to a future companion paper, please respond yes and provide the title in the space provided.</p>	No
<p>Preprint Has this submission been posted anywhere as a preprint?</p>	No
<p>Article Publishing Charge Journal of Lipid Research is an open access journal which charges an Article Publishing Charge (APC) to cover the cost associated with the publication process.</p> <p>All articles published Open Access will be immediately and permanently free on ScienceDirect for users to read, download, and use in accordance with the author's selected Creative Commons user license.</p>	As an Author, I acknowledge I need to pay the Article Publishing Charge if my manuscript is accepted for publication
<p>Conflicts of Interest Please indicate whether you and/or any author(s) have an actual or perceived conflict of interest with the contents of this article. For more information about conflicts of interest, click here.</p>	No author has an actual or perceived conflict of interest with the contents of this article. (If you click this button, please include the following statement in your manuscript PDF: The authors declare that they have no conflicts of interest with the contents of this article.)
<p>Data Availability Policy JLR requires authors to fully comply with our Data Availability Policy. ASBMB encourages authors to make all data available to readers through the use of public domain repositories, and requires</p>	I ACCEPT

<p>authors to deposit certain types of datasets into community-endorsed public repositories. Datasets that have been deposited into repositories must also be entered under the Datasets Deposition questions below. Data Availability Statements are required for all submissions.</p> <p>I acknowledge that I have read and accept the conditions set in the Data Availability Policy. I understand my manuscript will not proceed to an editorial evaluation until these conditions are met.</p>	
<p>Datasets Deposition Does your work contain or include any of the following: new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy); NMR chemical shift data; functional genomics data; nucleotide or protein sequences; any other data that was deposited into a public repository?</p> <p>Please answer "Yes" if any of the items listed apply.</p>	Yes
<p>Does your work report a new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy)? as follow-up to "Datasets Deposition"</p> <p>Does your work contain or include any of the following: new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy); NMR chemical shift data; functional genomics data; nucleotide or protein sequences; any other data that was deposited into a public repository?</p> <p>Please answer "Yes" if any of the items listed apply. "</p>	No
<p>Does your work contain NMR chemical shift data?</p>	No

<p>as follow-up to "Datasets Deposition</p> <p>Does your work contain or include any of the following: new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy); NMR chemical shift data; functional genomics data; nucleotide or protein sequences; any other data that was deposited into a public repository?</p> <p>Please answer "Yes" if any of the items listed apply.</p> <p>"</p>	
<p>Does your work include functional genomics data such as microarray, ChIP-seq, RNA-seq, or any other high-throughput functional genomic data?</p> <p>as follow-up to "Datasets Deposition</p> <p>Does your work contain or include any of the following: new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy); NMR chemical shift data; functional genomics data; nucleotide or protein sequences; any other data that was deposited into a public repository?</p> <p>Please answer "Yes" if any of the items listed apply.</p> <p>"</p>	<p>No</p>
<p>Does your work contain newly determined nucleotide or protein sequences?</p> <p>as follow-up to "Datasets Deposition</p> <p>Does your work contain or include any of the following: new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy); NMR chemical shift data; functional genomics data; nucleotide or protein sequences; any other data that was deposited into a public repository?</p> <p>Please answer "Yes" if any of the items listed apply.</p>	<p>No</p>

<p>"</p> <p>Does your work contain any other data that was deposited into a public repository (e.g., metabolomics, STRENDA, or Zenodo)? as follow-up to "Datasets Deposition"</p> <p>Does your work contain or include any of the following: new experimental 3-dimensional structure (x-ray crystallography, NMR spectroscopy, or cryoElectron Microscopy); NMR chemical shift data; functional genomics data; nucleotide or protein sequences; any other data that was deposited into a public repository?</p> <p>Please answer "Yes" if any of the items listed apply.</p>	<p>Yes</p>
<p>Enter the following information for each accession number (dataset ID), one per line, as follows: Dataset ID; direct URL (leading to that dataset ID); login details (if password protected access). Alternatively, indicate "Dataset provided in this submission". as follow-up to "Does your work contain any other data that was deposited into a public repository (e.g., metabolomics, STRENDA, or Zenodo)?"</p>	
<p>Mass Spectrometry Data</p> <p>Does your manuscript contain data reporting protein/peptide/glycan identification and/or quantification by mass spectrometry? Please make sure that your manuscript complies with our guidelines.</p>	<p>Yes</p>
<p>Human Studies</p> <p>Does your work report on any studies involving human subjects? (If yes, please ensure that the work adheres to our policies here.)</p>	<p>No</p>
<p>Animal Studies</p> <p>Does your work report on any studies involving animals? (If yes, please ensure that the work adheres to our policies here.)</p>	<p>No</p>
<p>Funding Acknowledgement</p> <p>Please confirm that you have mentioned all organizations that funded your research in the Funding and Additional Information Section section of your submission, including grant numbers</p>	<p>I confirm that I have mentioned all organizations that funded my research in the Acknowledgements section of my submission, including grant numbers where appropriate.</p>

where appropriate.

ATP-binding cassette transporters mediate differential glycosphingolipid biosynthesis

[REDACTED]

From the [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#To whom correspondence should be addressed: [REDACTED]

[REDACTED]

[REDACTED]

Running title: ABC transporters mediate GSL biosynthesis

Funding sources: This study was supported by a Canadian Institutes of Health Research team grant in Lysosomal Storage Disease Pharmaco-therapeutics, a Canadian NSERC award to C.A.L., a Research Institute Restrcomp graduate fellowship from the Hospital for Sick Children, an Ontario Graduate Scholarship and a graduate fellowship from the Department of Laboratory Medicine and Pathobiology, University of Toronto to M.B.

Abbreviations: B3GALT1, β -1,3-galactosyltransferase 1; B4GALT6, β -1,4-galactosyltransferase 6; Cer, ceramide; FAPP2, phosphatidylinositol-four-phosphate adapter protein 2; GCS, GlcCer synthase; GlcCer, glucosylceramide; GLTP, glycolipid transfer protein; GSL, glycosphingolipid; KD, knockdown; LacCer, lactosylceramide; Lc₃, lactotriaosylceramide; LCS, LacCer synthase; NBD, nitrobenzo-2-oxa-1,3-diazole; NC, negative control; siRNA, small interfering RNA; ST3GAL5, β -galactoside α -2,3-sialyltransferase 5, GM3 synthase; TMD, transmembrane domain.

Abstract

The cytosolic-oriented glucosylceramide (GlcCer) synthase is problematic, requiring nascent GlcCer translocation to the luminal Golgi membrane to access GSL anabolic glycosyltransferases. The mechanism by which GlcCer is flipped remains unclear. Using a GlcCer photoprobe, we identified ATP-binding cassette (ABC) transporters ABCA3, ABCB4 and ABCB10 as microsomal GlcCer-binding proteins in DU-145 prostate tumor cells. siRNA knockdown (KD) of these ABC transporters differentially blocked GSL synthesis assessed *in toto* and via metabolic labelling. KD of ABCA3 reduced acid/neutral GSLs but increased lactosylceramide (LacCer), ABCB4 preferentially reduced neutral GSLs, and ABCB10 reduced both neutral and acidic GSLs. KD of other ABC proteins implicated in GlcCer transport were also investigated. ABCA12 depletion preferentially decreased neutral GSLs. ABCB1 KD preferentially reduced gangliosides, but increased Gb₃. These results infer multiple ABC transporters provide distinct but overlapping GlcCer (and LacCer) pools within the Golgi lumen stacks for anabolism of different GSL series by metabolic channeling. Differential ABC family member usage/redundancy may fine tune GSL biosynthesis according to cell/tissue type. ABC transporters provide a new tool for the regulation of GSL biosynthesis and potential targets to reduce selected GSL species/subsets in GSL dysregulated diseases.

Keywords: ABC transporter, glucosylceramide flippase, glycolipids, glycosphingolipid, Golgi apparatus, proteomics, sphingolipids, transport.

Introduction

Glycosphingolipids (GSL) have many functional, structural and regulatory roles (1). They are involved in cell signaling, apoptosis, cell differentiation, proliferation, cell adhesion and pathogen entry (1,2). Aberrant GSL metabolism is pathologically associated with many diseases (1) such as GSL storage diseases (3), type II diabetes (4), atherosclerosis (5), lupus (6), asthma (7), cancer (8-10), multiple drug resistant tumours (11,12), metabolic syndrome (13), inflammation (14) and the neuropathies – ALS (15), Alzheimer's and Parkinson's disease (16,17). Inhibition of GSL synthesis alleviates disease symptoms (7,18-20). In addition, GSL biosynthesis is required for SARS-CoV-2 and influenza viral propagation (21). Understanding complex GSL synthesis is therefore crucial in generating the means for selective therapeutic

correction of GSL levels. Currently, the only approach is to inhibit all GSLs using glucosylceramide synthase (GCS) inhibitors such as Miglustat (22), and eliglustat (23,24), which can cause adverse side effects (25-28).

Glucosylceramide (GlcCer) is the precursor of >90% of mammalian GSLs, while galactosylceramide and fucosylceramide account for the remainder (1). GlcCer is synthesized from ceramide (Cer) by GCS on the cytosolic leaflet of the Golgi (29-31). GCS activity is widely distributed throughout the Golgi, with highest specific activity in the cis/medial-Golgi (30). Lactosylceramide (LacCer) is generated from GlcCer by LacCer synthase (LCS) on the Golgi luminal leaflet (32,33). LCS is localized throughout the Golgi (33,34) and TGN (35). LacCer is the diverging point for conversion into more complex GSLs - ganglio, globo, lacto, and neolacto series (1), also made within the Golgi lumen (33). However, the mechanism by which GlcCer translocates into the Golgi lumen still remains largely a matter of conjecture (35,36).

A few GlcCer transport pathways have been proposed thus far, which result in the synthesis of specific GSL-series. In non-vesicular GlcCer traffic, phosphatidylinositol-four-phosphate adapter protein 2 (FAPP2) transports cytosolic GlcCer from the *cis*- Golgi to the TGN, where it is translocated by a proposed ATP-dependent GlcCer flippase (35), possibly multidrug resistance protein 1 (MDR1, Pgp, ABCB1), to the luminal leaflet for neutral (i.e. globo-series) GSL synthesis (35). In vesicular GlcCer traffic, two routes have been implicated for acidic (i.e. gangliosides) GSL synthesis. GlcCer synthesized on the cytosolic leaflet of early Golgi membranes is translocated to the lumen by an uncharacterized ATP-dependent flippase and delivered to the TGN via vesicular transport (2,35). The second route proposes cytosolic GlcCer undergoes retrograde transport back to the ER via FAPP2 and is flipped by an ATP-independent flippase to the ER lumen and then to the TGN by vesicular transport (34). However, this has since been contradicted by studies showing FAPP2 knockdown does not decrease GM₃ synthesis (35).

ABCB1 is an ATP-dependent drug efflux pump which facilitates drug resistance in tumour cells (37). It is a member of the ATP-binding cassette (ABC) transporter superfamily, containing two cytoplasmic nucleotide-binding domains, and two transmembrane domains (TMDs) (38). ABCB1 was predicted to have more than 300 substrates (39), with a diverse range including drugs, peptides, phospholipids, and

sphingolipids (40,41). GlcCer was suggested as a substrate when ABCB1 transfected epithelial LLC-PK1 cells translocated C6-NBD (nitrobenzo-2-oxa-1,3-diazole)-GlcCer, C6-GlcCer and C8C8-GlcCer across the apical membrane, which was reduced by MDR inhibitors and energy depletion (42). However, ABCB1 has been found not only at the plasma membrane but also the Golgi complex (43). ABCB1 was first suggested as a potential mechanism for flipping GlcCer to the luminal leaflet of the Golgi for GSL biosynthesis when GSL levels were increased in ABCB1 retroviral cell transfection (44). Further studies have shown ABCB1 translocates short chained fluorescent GlcCer when reconstituted in proteoliposomes (41), which was inhibited by addition of C12-GlcCer (45). The first evidence of differential GSL anabolic regulation was our inhibition of LacCer and Gb₃, but not ganglioside, biosynthesis in ABCB1-expressing cell lines by cyclosporin A (46), supporting an ABCB1 role as a flippase selectively involved in globo-series GSL biosynthesis. However, cyclosporin A is not a specific ABCB1 inhibitor. The role of ABCB1 as a GlcCer flippase has been challenged, suggesting it only translocates short-chain GlcCer and not natural GlcCer (34). Interestingly, GCS overexpression in cancer has been shown to correlate with ABCB1 expression (47), and increased ABCB1 correlates with increased complex GSLs in drug resistant cells (48). Inhibiting GCS activity blocks ABCB1 overexpression (49), and vice versa (50), resensitizing drug resistant cells to chemotherapeutic drugs. This can involve additional ABC transporters (51). The mechanism by which ABCB1 flips phospholipid/GSL substrates remains unclear (52), but was suggested to resemble its drug efflux mechanism (40,41). In the inward-facing state the nucleotide-binding domains are separated, allowing substrate access to the drug-binding cavity (38). ATP binding causes a conformational change of the transporter to the outward-facing state and the nucleotide-binding domains dimerize which is stabilized by binding of two ATP molecules (38). The substrate affinity is lowered by the rearrangement of the drug-binding site, and flexibility of the outer membrane regions of the TM helices allows closure of the translocation pathway after the substrate is squeezed through and released (38). The transporter is reset to its inward-facing state after ATP hydrolysis (38).

The role of ABCB1 in GlcCer luminal translocation remains ill-defined and is unlikely the only mechanism. Other ABC proteins (ABCA12) and P4-ATPases (ATP10A and ATP10D) have been

implicated in GlcCer translocation, but have yet to be investigated as Golgi flippases in GSL biosynthesis (53-55). ABCA12 has been shown to be a GlcCer flippase in epidermal keratinocyte lamellar granules (54,56). Severe ABCA12 protein defects result in harlequin ichthyosis, a congenital skin disorder caused by skin lipid barrier loss (54). Immunofluorescent staining with ABCA12, GlcCer and Golgi apparatus antibodies showed co-localization of ABCA12 and GlcCer within the granular layer of keratinocytes, and showed ABCA12 distribution from the Golgi apparatus to cell periphery (57). Whether ABCA12 plays a role in GlcCer metabolism in non-epidermal tissues is unknown but ABCA12 expression is not limited to the skin (58). Significantly, when ABCA12^{-/-} keratinocytes were cultured, over time the abnormal phenotype and dysplastic GlcCer distribution was lost, concomitant with the upregulation of transporters ABCA17, ABCA1a, ABCC5, and ABCB11 (59), suggesting other ABC proteins can compensate for ABCA12 loss. Human P4-ATPases ATP10A and ATP10D were found to transport short chain NBD-GlcCer (53). ATP10D single nucleotide polymorphisms are associated with GlcCer elevation in plasma, and both ATP10A and ATP10D are linked to metabolic disease (60).

It is probable that other unidentified flippases are involved in Golgi GlcCer transport for GSL biosynthesis in addition to these other ill-defined GlcCer membrane transport proteins. Multiple Golgi and TGN flippases could be responsible for the formation of different GlcCer pools from which acidic and neutral or specific GSL series are derived. Defining such flippases would close a major gap in understanding GSL biosynthesis, perhaps providing new opportunities for more selective drug therapy to treat diseases affected by aberrant GSL metabolism.

In this study, we used novel GlcCer-based photoaffinity probes, XLA and XLB (61), to cross-link GlcCer binding proteins and putative GlcCer flippases in cell microsomes. Among the many cross-linked proteins, three flippase candidates, ABCA3, ABCB4 and ABCB10 were identified by mass spectrometry. siRNA knockdown studies show these transporters (and ABCB1, ABCA12) play crucial, overlapping but differential roles in cultured cell GSL metabolism.

Materials and methods

Reagents

2X PCR TaqFast MasterMix was purchased from abm. ¹⁴C-galactose was purchased from American Radiolabelled Chemicals. Chloroform, KCl, and methanol was purchased from Caledon Laboratory Chemicals. siRNA was purchased from GenePharma. 10X DNase I Reaction Buffer (200 mM Tris-HCl pH, 500 mM KCl, 20 mM MgCl₂), DNase I Amp Grade 1 U/μl, 25 mM EDTA, Oligo (dT) 20, dNTP Mix (10 mM each dATP, dGTP, dCTP and dTTP at neutral pH), 5X First-Strand Buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl₂), 0.1 M DTT, Lipofectamine® RNAiMAX Transfection Reagent, RNaseOUT Recombinant RNase Inhibitor, Streptavidin T1 Magnetic Dynabeads, and SuperScript III Reverse Transcriptase (RT) were purchased from Invitrogen. Pre-coated TLC sheets (Polygram SIL G/UV254) was purchased from Machery-Nagel. Glucosylceramide (glucocerebrosides) was purchased from Matreya LLC. HCl, iodoacetamide, NaOH, were purchased from Sigma-Aldrich. Opti-MEM® I Reduced Serum Medium, sequencing grade modified trypsin porcine 20 μg, and TRIzol® Reagent was purchased from ThermoFisher Scientific. Sep-Pak Vac 6cc (1g) certified C18 cartridges were purchased from Waters. Minimum Essential Medium (MEM), Phosphate-Buffered Saline (D-PBS), Fetal Bovine Serum (FBS), Trypsin (0.05%)/EDTA was purchased from Wisent Inc. DU-145 cells were kindly supplied by Dr. N. Fleshner, University of Toronto. GLTP was kindly provided by Dr. Thorsten Lang, Department of Membrane Biochemistry at the Life & Medical Sciences (LIMES) Institute, University of Bonn, Germany.

Cell culture

DU-145 cells were grown in MEM supplemented with 10% FBS at 37°C, and passaged using D-PBS and 0.05% trypsin/EDTA.

Proteomics

To identify putative GlcCer flippases, XLA and XLB were delivered by GLTP and cross-linked to DU-145 microsomal proteins as in (61). Samples were solubilized with 1X radioimmunoprecipitation assay (RIPA) buffer (1X TBS, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 1% triton X- 100, 0.5% sodium

deoxycholate), and centrifuged at 10,000 g for 10 min at room temperature. Supernatant containing cross-linked biotinylated proteins was collected and purified with MyOne Streptavidin T1 Magnetic Dynabeads. Before purification, Dynabeads were vortexed for 30 sec, aliquoted into 1.5 ml microtubes, washed with 1X RIPA buffer three times using μ MACS Separation Unit magnet. After Dynabeads were washed, they were incubated with cross-linked protein samples with shaking for 30 min at room temperature. Unbound supernatant was decanted, and beads were washed with 1X RIPA buffer three times, and D-PBS two times. Protein coupled beads were stored at - 20°C until use. Protein- bound bead samples were denatured in 8 M urea, 50 mM Tris-HCl pH 8 and 4 mM DTT, heated at 60°C for 45 min. Samples were cooled to room temperature and cysteine residues were alkylated with 10 mM iodoacetamide incubated in the dark at room temperature for 15 min. Samples were diluted with 50 mM NH_4HCO_3 pH 7.8 until urea concentration was less than 1 M. CaCl_2 from 100 mM stock was added to make a final concentration of 1 mM. Sequencing grade modified porcine trypsin was dissolved in 100 μ l 0.01% TFA (0.2 μ g/ μ l), aliquoted into 10 μ l shots and stored at - 20°C until use. Proteins were digested by 1:100 (w/w) trypsin:protein, incubated at 37°C with shaking for 24 h. Samples were analyzed by LC/MS/MS Orbitrap- Elite, performed by the SPARC BioCentre (Molecular Analysis), The Hospital for Sick Children, Toronto, Canada.

Experimental design and statistical rationale

For identification of potential GlcCer flippases involved in GSL biosynthesis, GlcCer analogue photoprobe stereoisomers XLA and XLB were cross-linked in DU-145 cell microsomes. This human prostate carcinoma cell line was used for its extensive acidic and neutral GSL content. The sample size was $n = 1$ and there were no replicates performed which was acceptable for our study as the GlcCer cross-linker probes (XLA and XLB) were only used to identify GlcCer binding proteins as candidate GlcCer flippases. Actual candidate flippase involvement in GSL biosynthesis would be confirmed by cellular knockdown studies.

There were three different controls employed. “Control” sample with microsomes but without cross-linker to rule out endogenous biotinylated proteins. “XLA + GLTP” and “XLB + GLTP” samples,

contained as stated, but without microsomes. These were used to exclude any contaminated proteins present in GLTP when GLTP was used for cross-linker delivery and insertion into the microsomal membranes.

Tandem mass spectrometry search parameters and acceptance criteria

Peaks were assigned via Proteome Discoverer version 1.4.0.288. Charge state deconvolution and deisotoping were not performed. All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version 1.4.0.288) and X! Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). Sequest was set up to search Uniprot-Human-Nov12015.fasta (unknown version, 42087 entries) assuming the digestion enzyme trypsin with 2 max missed cleavages. X! Tandem was set up to search a subset of the Uniprot-Human-Nov12015 database (unknown version, 84264 entries) also assuming trypsin with 2 max missed cleavages. Sequest and X! Tandem were searched with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 10.0 PPM. Carbamidomethyl of cysteine was specified in Sequest and X! Tandem as a fixed modification. Deamidated of asparagine and glutamine and oxidation of methionine were specified in Sequest as variable modifications. Glu->pyro-Glu of the N-terminus, ammonia-loss of the N-terminus, gln->pyro-Glu of the N-terminus, deamidated of asparagine and glutamine and oxidation of methionine were specified in X! Tandem as variable modifications.

Scaffold (version Scaffold_4.8.7, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability by the Scaffold Local FDR algorithm. Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least 1 identified peptide. Protein probabilities were assigned by the Protein Prophet algorithm (62). Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony.

siRNA transfection

DU-145 cells were transfected in 6-well plates at 80% confluency. Lipofectamine RNAiMAX Transfection Reagent (75 pmol) and 75 pmol siRNA (see **Table S4** for sequences) were diluted in 250 μ l Opti-MEM I Reduced Serum Medium and incubated at room temperature for 5 min. The siRNA-reagent complex (250 μ l) was added to each well containing 2 ml of EMEM +10% FBS. Cells were incubated at 37°C for 24 h, washed with D-PBS, and incubated at 37°C in fresh EMEM +10% FBS for 24 h. Cells were then used for subsequent GSL extraction or GSL metabolic labeling, and transfection efficacy was analyzed by RNA extraction and RT-PCR.

Glycosphingolipid metabolic labeling

Post transfection, cells were incubated with 1.5 μ Ci 14 C-galactose diluted in 2 ml/well MEM +10% FBS for 5 h at 37°C. Prior to GSL extraction, cells were washed with D-PBS twice.

RNA extraction

For dissociation of the nucleoprotein complex, media was removed from 6-well plate, replaced with 1 ml/well of TRIzol Reagent and incubated at room temperature for 5 min. Samples were transferred to 1.5 ml microtubes, and mixed vigorously by hand for 15 sec with 0.2 ml chloroform. Samples were incubated at room temperature for 3 min, centrifuged at 12,000 g for 15 min at 4°C, and the aqueous phase containing RNA was transferred to a new 1.5 ml microtube. To precipitate the RNA, samples were incubated at room temperature with 0.5 ml isopropanol for 10 min. RNA was collected by centrifugation at 12,000 g for 10 min and supernatant was discarded. RNA pellet was washed in 1 ml of 75% ethanol, and centrifuged at 7,500 g for 5 min at 4°C. After supernatant was discarded, RNA pellet was vacuum dried. RNA was suspended in DEPC-treated water and incubated at 60°C for 10 min. The RNA was quantified with NanoDrop 2000c Spectrophotometer and stored at -80°C until use.

DNase digestion

For DNA digestion of single and double-stranded DNA, 1 μ g RNA sample was incubated at room temperature for 10 min with 1 μ l 10X DNase I Reaction Buffer, 1 μ l DNase I Amp Grade 1 U/ μ l, and DEPC-

treated water to final volume of 10 μ l. DNase I was inactivated by incubation with 1 μ l of 25 mM EDTA at 65°C for 10 min.

First-strand synthesis

For first-strand synthesis of cDNA, 1 μ g DNase I treated RNA samples were incubated with 1 μ l oligo (dT) 20, and 1 μ l dNTP Mix at 65°C for 5 min, and incubated on ice for 5 min. Samples were briefly centrifuged, and incubated with 4 μ l 5X First-Strand Buffer, 1 μ l 0.1 M DTT, 1 μ l RNaseOUT Recombinant RNase Inhibitor and SuperScript III RT at 50°C for 60 min. Reaction was inactivated by incubation at 70°C for 15 min. Synthesized cDNA was stored at -20°C until use as a template for RT-PCR amplification.

Reverse transcription polymerase chain reaction

RT-PCR was used for cDNA amplification. cDNA templates from first-strand synthesis (1.5 ng) were amplified using 400 nM forward and reverse primers (**Table S5**), 1X PCR TaqFast MasterMix with dye, and DEPC-treated water to a final volume of 50 μ l. Samples were incubated in thermal cycler programed to the following: Step 1/initial denaturation: 3 min at 94°C. Step 2/denaturation: 30 sec at 94°C. Step 3/annealing: 30 sec at primer specific temperature. Step 4/extension: 1 min at 72°C. Step 5: Repeat steps 2 to 4 for primer specific number of cycles. Step 6/final extension: 10 min at 72°C. Step 7/final holding: 4°C until use or storage at -20°C. Amplification products were analyzed by gel electrophoresis with 1% agarose gel in 0.5X TAE and stained with GelRed (1:10000, v/v). Gels were imaged with BioRad ChemDoc MP Imaging System (Nucleic Acid GelRed setting).

Glycosphingolipid extraction

Six-well plates seeded with DU-145 cells were washed with D-PBS, and incubated in 1 ml 0.5 N NaOH/methanol at 37°C for 1 h to saponify phospholipids. Samples were transferred to glass test tube, neutralized with aqueous 0.5 N HCl, diluted with water (total volume less than 30% methanol), and desalted by C18 Sep-Paks. GSL extracts were dried under nitrogen and low heat, and if necessary stored at -20°C until use.

Thin-layer chromatography

GSLs extracted from 6-well plates were dissolved in $\text{CHCl}_3:\text{CH}_3\text{OH}$ (2:1, v/v) before loading to silica-coated TLC plate with Hamilton syringe. Samples were resolved first with $\text{CHCl}_3:\text{CH}_3\text{OH}$ (98:2, v/v) mobile phase, dried, and subsequently resolved with $\text{CHCl}_3:\text{CH}_3\text{OH}:\text{H}_2\text{O}$ (60:40:8, v/v/v). For total GSL analysis, samples were visualized by staining with 0.5% orcinol in 3M H_2SO_4 and incubation at 130°C. Metabolically labeled GSLs were exposed to film for 2 days and developed for visualization. GSL bands were quantified using ImageJ. All knockdowns were calculated as a percentage of the mean value of NC for each trial, and plotted with GraphPad Prism 7.

Analysis of Gb₃ isoforms

DU-145 cell Gb₃ isoforms were analyzed post ABC transporter siRNA transfection by normal-phase ultraperformance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) as described (63). Results were plotted using GraphPad Prism 7.

Results

Proteomic analysis

For identification of potential GlcCer flippases, GlcCer-based photoprobe stereoisomers XLA and XLB (see **Figure S1** in supplemental data for structure) were cross-linked in DU-145 cell microsomes \pm glycolipid transfer protein (GLTP) for cross-linker delivery and insertion into the microsomal membranes as previously (61). DU-145 cells were chosen because of their exemplary acidic and neutral GSL content. Bound proteins were purified by streptavidin-coupled magnetic beads, denatured, digested, and identified by mass spectrometry. Control sample (without cross-linkers) was compared to cross-linked microsomal samples to determine relevant proteins (**Figure 1**). There were 317 microsomal proteins cross-linked with XLA (**Figure 1A**), but only 5 proteins cross-linked when GLTP delivered XLA (**Figure 1B**). Nineteen proteins were identified when cross-linked with XLB (**Figure 1C**), but 404 proteins were cross-linked with XLB when delivered with GLTP (**Figure 1D**). Cross-linked GLTP was identified in all samples containing GLTP. In the XLB and GLTP sample, three ABC transporter candidate flippases were identified, ABCA3,

ABCB4 and ABCB10, together with one bona fide GlcCer binding protein, β -1,3-galactosyltransferase 1 (B3GALT1) (64). For information on protein and peptide identification see **Table S1 and S2** in supplemental data. The list of proteins cross-linked when XLB was delivered with GLTP can also be found in supplemental data (**Table S3**). Relationships between identified proteins, ABCB1, ABCA12, and glycosyltransferases were determined using GeneMANIA (**Figure 1E**). ABCB4 shows a predicted functional relationship with ABCB1, and is co-expressed with B4GALT6 (β -1,4-galactosyltransferase 6, LacCer synthase), ST3GAL5 (β -galactoside α -2,3-sialyltransferase 5, GM₃ synthase) and ABCB1. B3GALT1 (Lc₄ synthase) which was cross-linked, has genetic interactions with ABCB1 and ABCB4.

siRNA screen in DU-145 cells

The putative GlcCer flippases identified by proteomics (ABCA3, ABCB4, ABCB10) were depleted by siRNA in DU-145 cells to investigate effects on GSL metabolism. Other protein knockdowns were also conducted, GCS, and suspected GlcCer translocases ABCB1 and ABCA12. Since not all siRNA sequences deplete gene expression equally, three siRNA sequences were made for each gene and screened for knockdown efficacy. siRNA were named by protein name and the position acted on in the gene sequence. DU-145 cells were transiently transfected with siRNA. mRNA was extracted, and analyzed by reverse transcription polymerase chain reaction (RT-PCR) amplification and agarose gel electrophoresis. Negative control (NC) siRNA was provided as a scrambled sequence. GCS-833 and ABCB1-3323 knockdowns were most effective in DU-145 cells (**Figure S2A and F** respectively) among other siRNA sequences (not shown). Of ABCA3-1006, ABCA3-1154, and ABCA3-4495, the most effective knockdown was ABCA3-1006 (**Figure S2B**). ABCB4-980 knockdown was more effective than ABCB4-1447 and ABCB4-2046 (**Figure S2C**). ABCB10-841 was the most effective between ABCB10-841, ABCB10-1039, and ABCB10-1506 (**Figure S2D**). ABCA12-2663 depleted ABCA12 RNA more than ABCA12-667 and ABCA12-4771 (**Figure S2E**).

GCS depletion significantly reduced all GSLs

GCS knockdown was a control to estimate the maximum possible GSL depletion. DU-145 cells were transfected with GCS-833 siRNA. Knockdown was confirmed by RT-PCR (**Figure 2A**). GSLs were extracted and total GSL levels were analyzed by thin-layer chromatography (TLC) stained with orcinol (**Figure 2B**). Quantified GSLs from TLC plates (**Figure 2C**) show LacCer was reduced by a mean of $26.1\% \pm 18.1$, Gb₃ by $31.9\% \pm 10.7$, Gb₄ by $38.5\% \pm 6.8$, and GM₃ by $18.8\% \pm 8.2$. GlcCer could not be quantified due to interference from orcinol negative species. GM₂ was not quantified due to inconsistent resolution.

GSLs stained with orcinol measured total GSL levels including residual pre-knockdown GSLs. To observe effects on GSL anabolism post knockdown exclusively, DU-145 cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection with GCS-833 siRNA. **Figure 2D** shows GCS transcript was depleted by knockdown. GSLs were extracted, resolved by TLC, and newly synthesized GSLs detected by autoradiography (**Figure 2E**). Quantified GSLs (**Figure 2F**) show a mean reduction of GlcCer by $78.1\% \pm 2.4$, LacCer by $73.9\% \pm 1.4$, Gb₃ by $64.4\% \pm 1.4$, Gb₄ by $66.8\% \pm 1.5$, and GM₃ by $71.2\% \pm 3.4$. GM₂ band appears reduced in representative TLC plate, however it was not quantified due to inconsistent resolution.

Therefore, all GSLs were reduced in both GCS knockdown studies of total GSL and metabolically labeled GSL analyses. However, GSL differences between NC and GCS knockdown are significantly greater (approximately two-fold) in metabolically labeled GSLs than total GSLs. Maximum (possible) inhibition for all GSLs was ~70%.

ABCA3 knockdown decreased complex GSLs, but increased LacCer

ABCA3 was depleted by ABCA3-1006 siRNA transfection in DU-145 cells to investigate its role in GSL biosynthesis. Knockdown was verified by RT-PCR (**Figure 3A**). TLC separated GSLs were detected by orcinol stain (**Figure 3B**). Quantified GSLs (**Figure 3C**) show GlcCer was reduced by mean of $4.1\% \pm 6.5$, Gb₃ by $16.0\% \pm 3.7$, Gb₄ by $18.26\% \pm 4.1$, and GM₃ by $15.2\% \pm 7.2$, but LacCer was increased by $13.9\% \pm 7.0$. GM₂ was reduced but not quantified.

DU-145 cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection. RT-PCR shows ABCA3 RNA was reduced by transient knockdown (**Figure 3D**). GSLs were separated by TLC

(**Figure 3E**) and autoradiograms were quantified (**Figure 3F**). GlcCer was reduced by a mean of $11.0\% \pm 4.3$, Gb₃ by $41.7\% \pm 2.3$, Gb₄ by $48.7\% \pm 4.4$, and GM₃ by $33.2\% \pm 2.8$. In contrast, LacCer was increased by $11.8\% \pm 4.1$. The representative TLC shows GM₂ was reduced, but was not quantified.

In summary, ABCA3 depletion in DU-145 cells resulted in decreased Gb₃, Gb₄, GM₃, but increased LacCer. All GSLs (except LacCer) were significantly more reduced when metabolically labeled.

ABCB4 knockdown preferentially reduced neutral GSLs

ABCB4 was depleted by ABCB4-980 siRNA transfection in DU-145 cells to determine its effects on GSL metabolism. Transfection was confirmed by RT-PCR (**Figure 4A**). Extracted GSLs were separated by TLC and stained with orcinol (**Figure 4B**). Quantified GSLs (**Figure 4C**) show ABCB4 depletion reduced GlcCer by a mean of $23.7\% \pm 2.5$, LacCer by $9.8\% \pm 5.2$, Gb₃ by $21.8\% \pm 2.5$, Gb₄ by $26.4\% \pm 4.7$ and GM₃ by $5.8\% \pm 3.5$. GM₂ was not quantified, however it does not appear reduced.

DU-145 cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection. Knockdown efficacy was confirmed by RT-PCR (**Figure 4D**). GSLs were resolved by TLC (**Figure 4E**), and autoradiograms were quantified (**Figure 4F**). ABCB4 knockdown decreased GlcCer by a mean of $24.0\% \pm 3.9$, LacCer by $31.8\% \pm 3.1$, Gb₃ by $53.4\% \pm 3.2$, Gb₄ by $68.1\% \pm 2.8$, and GM₃ by $12.1\% \pm 8.8$. GM₂ appears slightly reduced in the representative TLC plate.

ABCB4 depletion in DU-145 cells decreased all GSLs, but preferentially reduced neutral GSLs LacCer, Gb₃ and Gb₄. These changes were particularly evident in the metabolically labeled GSLs compared to total GSLs observed by orcinol stain.

ABCB10 knockdown reduced both neutral and acidic GSLs

ABCB10 was depleted by ABCB10-841 siRNA transfection in DU-145 cells to determine its role in GSL biosynthesis. Knockdown efficacy was observed by RT-PCR (**Figure 5A**) which shows reduced ABCB10 mRNA transcript. GSLs were examined by TLC stained with orcinol (**Figure 5B**). Quantified data show decreased GlcCer by a mean of $20.2\% \pm 4.4$, LacCer by $16.4\% \pm 5.3$, Gb₄ by 9.9 ± 6.3 , and GM₃

by 10.0 ± 6.7 , but Gb₃ had a minor increase of $0.5\% \pm 6.0$ (**Figure 5C**). GM₂ was not quantified, however it appears slightly reduced in the representative TLC plate.

DU-145 cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection. ABCB10 mRNA transcript reduction was confirmed by RT-PCR (**Figure 5D**). Radiolabeled GSLs were detected by TLC autoradiography (**Figure 5E**). Quantified GSLs (**Figure 5F**) revealed decreased GlcCer by a mean of $30.2\% \pm 3.5$, LacCer by $28.4\% \pm 4.5$, Gb₃ by $19.0\% \pm 3.1$, Gb₄ by $42.3\% \pm 1.6$, and GM₃ by $32.0\% \pm 7.9$. GM₂ appears reduced in representative TLC plate, but was not quantified.

In summary, ABCB10 depletion in DU-145 cells decreased both neutral and acidic GSLs. However, these decreases were significantly greater in metabolically labeled GSLs than total GSLs.

ABCA12 depletion preferentially reduced neutral GSL biosynthesis

ABCA12 has been shown to transport GlcCer across membranes of lamellar bodies in keratinocytes (56), however its role in GSL biosynthesis has not been examined. Therefore, we transiently knocked down ABCA12 in DU-145 cells to determine its role in GSL metabolism. Cells were transfected with ABCA12-2663 siRNA, and ABCA12 mRNA depletion was confirmed by RT-PCR (**Figure 6A**). GSLs were observed by orcinol stained TLC (**Figure 6B**), and quantified (**Figure 6C**). ABCA12 knockdown reduced LacCer by a mean of $15.4\% \pm 5.1$, GM₃ by $6.2\% \pm 2.6$, and negligible decreased Gb₃ by $1.9\% \pm 7.9$, and Gb₄ by $1.0\% \pm 5.5$. GlcCer was not quantified due to orcinol negative band interference. GM₂ was also not quantified due to inconsistent resolution, however it appears unchanged in the representative TLC.

DU-145 cells were metabolically labelled with ¹⁴C-galactose for 5 h post transfection. ABCA12 mRNA depletion was confirmed by RT-PCR (**Figure 6D**). Newly synthesized GSLs were analyzed by TLC autoradiography (**Figure 6E**). Quantified GSLs (**Figure 6F**) show GlcCer was reduced by a mean of $25.9\% \pm 4.0$, LacCer by $45.4\% \pm 3.5$, Gb₃ by $46.2\% \pm 1.9$, Gb₄ by $54.1\% \pm 9.0$, and GM₃ by $25.0\% \pm 3.2$. GM₂ appears to be reduced in representative TLC plate, but was not quantified.

In summary, ABCA12 knockdown changes in GSL levels were minimal when total GSLs were analyzed. However, neutral GSLs were preferentially reduced when the cells were metabolically labeled.

ABCB1 knockdown preferentially reduced gangliosides but increased Gb₃

ABCB1 is currently the only transporter proposed to flip GlcCer across the Golgi membrane for complex GSL biosynthesis. To elucidate the specific role of ABCB1 in GSL biosynthesis, it was knocked down in DU-145 cells by ABCB1-3323 siRNA transfection. Depletion of ABCB1 transcript was verified by RT-PCR (**Figure 7A**). Total GSLs resolved by TLC were detected by orcinol (**Figure 7B**), and quantified (**Figure 7C**). LacCer was decreased by a mean of $22.2\% \pm 7.5$, Gb₃ by $5.8\% \pm 11.1$, Gb₄ by $19.5\% \pm 9.2$, GM₃ by $26.3\% \pm 8.1$. GlcCer was not quantified due to an interfering orcinol negative species. GM₂ was also not quantified due to inconsistent resolution, however it appears somewhat reduced in the representative TLC plate.

To examine the effect of ABCB1 knockdown on newly synthesized GSLs DU-145 cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection. RT-PCR shows ABCB1 mRNA was reduced by knockdown with ABCB1-3323 siRNA (**Figure 7D**). GSLs were detected by TLC autoradiography (**Figure 7E**), and quantified (**Figure 7F**). GlcCer was decreased by a mean of $36.2\% \pm 2.5$, LacCer by $23.5\% \pm 6.5$, Gb₄ by $15.3\% \pm 7.2$, and GM₃ by $47.6\% \pm 4.6$, but Gb₃ increased by $27.4\% \pm 5.3$. GM₂ appears reduced in the representative TLC plate, but was not quantified.

Both total GSLs and metabolically labeled GSLs have similar results for LacCer, GM₃ and Gb₄. Metabolic data shows significant increase in Gb₃, while total GSL data shows insignificant decrease. GM₃ is substantially more decreased in metabolic data. Overall, ABCB1 knockdown preferentially decreased GM₃ but increased Gb₃.

Changes in Gb₃ levels post ABC transporter knockdowns were not acyl chain selective.

To examine if ABC transporters preferentially transport GlcCer with specific acyl chain compositions, Gb₃ content was analyzed by mass spectrometry post ABC knockdowns. Depletion of ABCA3, ABCB1, ABCB4 or ABCB10 resulted in no preferential change in Gb₃ species (**Figure S3**).

Discussion

We previously demonstrated GLTP enhancement of (luminal) microsomal GSL synthesis, which was amplified by ATP, consistent with GLTP delivery of cytosolic nascent GlcCer to an ATP-dependent step (ATP-dependent flippase) (61). GLTP was also established as a cytosolic GSL transporter in model membranes (65,66). Therefore, we used GLTP to deliver and insert our GlcCer analogue cross-linkers (XLA and XLB **Figure S1**) into microsomal membranes to identify GlcCer binding putative undiscovered GlcCer flippases. Three ABC transporter candidate flippases, ABCA3, ABCB4 and ABCB10, were identified by mass spectrometry only when DU-145 microsomal proteins were cross-linked by GLTP delivered XLB. B3GALT1 (Lc₄ synthase), which is a downstream glycosyltransferase in GSL synthesis (64), was also identified. Since XLB could be converted into its LacCer form in microsomes (61), it is feasible to cross-link downstream glycosyltransferases with XLB (61). Furthermore, B3GALT1 has been shown to use GlcCer as a substrate in addition to Lc₃ (64).

Major differences between the XLA and XLB proteomics results were observed. This is the direct result of these cross-linkers being diastereomers containing the fatty acid moieties in different orientations (61). XLA and XLB precursors (2A-GlcCer A and B respectively derived from coupling a D,L 2-aminohexadecanoic acid mixture) ran very differently on TLC due to a 2A-GlcCer A intramolecular hydrogen bond between the primary amine of the fatty acid moiety and hydroxyl group of the sphingosine moiety (61). Thus conformation of fatty acid stereoisomers alone can have a major impact on GSL polarity. Even after 2A-GlcCer A conversion to XLA (primary amine conversion to amide linkage), XLA was more hydrophilic than XLB. This was supported by the significant number of XLA cross-linked microsomal proteins when delivered as micelles compared to XLB. XLA was better able to incorporate into microsomal membranes as micelles than via GLTP delivery. GSL acyl structure is key for GLTP binding (67). The XLA acyl chain orientation appears to prevent or slow its off-rate from GLTP, resulting in cross-linked GLTP and a significantly lower number of cross-linked microsomal proteins compared to XLB under the same conditions. This is supported by previous data showing XLA was not converted to its LacCer analogue in microsomes (unlike XLB), due to restricted access of the glucose 4'OH required for LCS action, yet XLA still inhibited NBD-LacCer synthesis from NBD-GlcCer (61). XLA fatty acid chain orientation could

prevent its translocation or interaction with GlcCer flippases since flippase activity could be acyl chain conformation selective. Furthermore, XLA had a lower affinity for GLTP than XLB (61). The lack of LCS, ABCB1, or ABCA12 cross-linking may be due to a lower XLB affinity for these proteins compared to native GlcCer, in addition to their low protein expression (ABCA12 and ABCB1 required high cycling for RT-PCR suggesting low mRNA levels, **Figure 6 and 7**) in DU-145 cells. One method to ameliorate this would be to deplete or inhibit GCS to reduce endogenous GlcCer before cross-linking. However, this could potentially reduce expression of GlcCer flippases, since GCS expression has been shown to correlate with ABCB1 expression (47).

Candidate flippases were selected because they are in the same protein family as ABCB1 which has known GlcCer flippase activity (68) and many family members are lipid flippases (69). However, none of these cross-linked candidates have been previously shown to interact with GlcCer or be involved with other GSLs.

ABCA3 plays a role in pulmonary surfactant formation by transporting phospholipids into lamellar bodies (70,71). Lung surfactant is a mixture of cholesterol, phospholipids and surfactant protein formed and stored in lamellar bodies of lung alveolar type II pneumocytes until secretion (70). Mutations in ABCA3 result in rare lung disorders (71,72). Interestingly, lung surfactant protein SP-A binds glucosylceramide and other neutral GSLs (73), therefore GlcCer may play a role in surfactant formation through translocation into lamellar bodies by ABCA3.

ABCB4 has been suggested as a phospholipid floppase, which flops PC from the inner to the outer leaflet of the canalicular membrane, making PC available for extraction into bile (42). Defects in ABCB4 cause intrahepatic cholestasis (74). ABCB4 (also known as MDR3) is closely related to ABCB1 (78% identity (75-77)), and like ABCB1, can act as a drug efflux pump (78) contributing to tumour drug resistance (77,79). Interestingly, ABCB4 is also implicated in glucose metabolism (80), and GSLs play a key role in diabetes (81).

ABCB10 is a δ -aminolevulinic acid transporter (82), in the inner mitochondrial membrane involved in heme synthesis and oxidative stress protection (83). The location of the nucleotide binding domains and

conformation suggests it transports substrates out of the mitochondrial matrix (84,85). Interestingly, ganglioside GD3 acts as an apoptotic regulator by interacting with mitochondria and recruiting apoptotic pathways (86). GM₁-accumulation at GSL-enriched microdomains in mitochondrial-associated ER membranes may influence Ca²⁺ mediated apoptotic signaling (87). Diabetic heart tissue has increased mitochondrial LacCer, with decreased calcium retention capacity and respiration, suggesting LacCer as the primary sphingolipid responsible for mitochondrial defects (88). Therefore, ABCB10 may play a role in GD3, GM₁ and/or LacCer regulation.

GCS knockdown was used as a positive control to determine the maximal extent of GSL depletion. All GSLs were more significantly reduced when GSLs were metabolically labeled than when total content was stained with orcinol. This was also true for all ABC transporter KDs, especially ABCA12. Metabolic labelling assesses *de novo* GSL biosynthesis, while orcinol detection of TLC separated GSLs gives an index of total GSL content, the sum of anabolism, catabolism and trafficking. The reduction of GSL synthesis may itself alter GSL trafficking (89,90), and hence lysosomal degradation.

All three putative GlcCer flippases identified by proteomics markedly affected GSL biosynthesis when depleted by siRNA transfection. ABCA3 knockdown reduced higher order GSL synthesis but increased LacCer production, possibly the result of increased GlcCer availability to a LacCer synthase where subsequent anabolic glycosyltransferases are not present. ABCB4 knockdown preferentially reduced globo-series GSLs as opposed to gangliosides. This suggests it is involved in the non-vesicular GSL glycosylation pathway, where it translocates FAPP2 delivered GlcCer across the TGN membrane, for globo-series synthesis (35). ABCB10 depletion reduced neutral and acidic GSLs. This suggests ABCB10 is a flippase involved in both vesicular and non-vesicular GSL glycosylation pathways, where it translocates GlcCer both at the *cis*-Golgi and the TGN.

ABCA12 and ABCB1 were not identified in the proteomics results, however they have been shown to interact with GlcCer (41,57). ABCA12 knockdown reduced LacCer but did not show a significant change in Gb₃, Gb₄ or GM₃ when total GSLs were analyzed. However, when the cells were metabolically labeled neutral GSLs were preferentially reduced. These differences between total and metabolic results could be

due to compensatory feedback mechanisms resisting changes in GSL levels by slowing or restricting the rate of GSL catabolism when *de novo* GSL biosynthesis is inhibited. ABCB1 knockdown preferentially reduced gangliosides, and decreased neutral GSLs except for Gb₃ which increased. Increased Gb₃ suggests increased GlcCer availability for a Gb₃ specific pathway unavailable to Gb₄ synthase. This is similar to the effect of fumonisin on GSL synthesis (91); the major metabolite of fumonisin is aminopentol which is a ABCB1 substrate (92). These ABCB1 knockdown results are contrary to published data where ABCB1 inhibition with cyclosporin A decreased LacCer and Gb₃ synthesis (46). However, this may be due to inhibition of ABCB4 by cyclosporin A (93) rather than ABCB1. Overexpression of ABCB1 in Madin-Darby canine kidney cells resulted in increased GlcCer, LacCer, and Gb₃ (44), and ovarian cancer cells that overexpress ABCB1 have increased GlcCer (no change in GCS expression) and lower levels of LacCer and gangliosides (94). Overexpression could force ABCB1 localization to the TGN in addition to the Golgi cisternae, as shown with GM₃ synthase overexpression (35). It is noteworthy that these findings were from a different cell line than the DU-145 cells used in our knockdown studies, suggesting the role of ABC transporters in GSL biosynthesis within the Golgi/TGN may be tissue and/or cell type dependent. Mouse *mdr1a/b* knockdown results in decreased GSL levels in skin fibroblasts, but brain GSLs are unaltered (95), further indicating a cell-type dependent role of ABCB1 in GSL synthesis. In cross breeding of Fabry and ABCB1 knockout mice, we found only heart and spleen showed reduced GlcCer whereas LacCer was generally elevated in these tissues and Gb₃ was not affected (96). It has been argued that lack of a clear phenotype for MDR knockout mice is not consistent with a physiological function (97), however we show in this study that there is a marked overlap and redundancy for ABC proteins as GlcCer flippases.

GSL synthesis is restricted by glycosyltransferases sub-Golgi localization, but does not follow a straightforward pathway from the *cis* to *trans*-Golgi to synthesize complex GSLs (35,98). Knockdown of ABC transporters in DU-145 cells differentially affected GSL biosynthesis suggesting separate and overlapping Golgi pools of GlcCer for differential GSL synthesis, which expands the current model (2). GlcCer synthesized on the cytosolic leaflet of the *cis*-Golgi can follow two pathways (**Figure 8**). For ganglioside GSL synthesis, GlcCer can be translocated by Golgi-selective flippases to the lumen and

transported through the Golgi cisternae and TGN via vesicular transport to the cell surface. For globo-series GSL synthesis GlcCer is transported to the TGN by FAPP2, where it is translocated to the lumen by TGN-selective flippases. ABCB4 and ABCA12 are likely a TGN-selective flippase (globo-series pathway), while, ABCA3 and ABCB10 are likely non-selective flippases. ABCB1 is likely a Golgi-selective flippase (gangliosides pathway) in DU-145 cells specifically.

We (99) and others (100,101) have shown that the fatty acid component of membrane GSLs modulates their receptor function and might be considered also to affect ABC GlcCer flippase activity. Mass spectrometry of a representative GSL (Gb₃) after each ABC transporter knockdown showed no change in fatty acid content, consistent with no ABC flippase GlcCer fatty acid preference.

The fact that ABC depletion can increase certain GSLs means their presence can suppress certain otherwise operative GSL biosynthetic pathways. These results are consistent with metabolic substrate channeling (102), whereby the product of one enzyme reaction, in this case, at a potential branch point, is directly transferred to only one of several possible next enzymes in a given pathway. Several such glycosyltransferase complexes in GSL biosynthesis have been described (103-105). **Figure 8** shows a schematic of potential ABC anabolic channels in DU-145 cell Golgi cisternae/TGN. Some GlcCer, and subsequently LacCer, pools are not available for ganglioside biosynthesis, whereas other pools are not used for globo-series GSL synthesis. In addition, some LacCer is not available for downstream GSL synthesis (counteracted by ABCA3), and Gb₃ can be made without access to Gb₄ synthase, from a separate channelled LacCer source (counteracted by ABCB1). The distinction between ganglioside and globo-series GSL precursor LacCer pools may extend to other GSL series, and relate to distinct changes in GSL series during differentiation (106).

It is possible that non-GSL ABC transporter substrates (e.g. brefeldin A (107), fumonisin (92), PS (108) for ABCB1, PC for ABCB4 (42), ABCA3 (109)) could affect GSL biosynthesis. Cooperative multiple drug binding by ABCB1 to promote drug transport (110,111) may provide a kinetic basis. Substrates can induce or stimulate ABCB1 efflux (112). Endogenous/exogenous substrates for ABCB1 (113), (or other ABC transporters) could therefore provide an unsuspected means to adjust cellular GSL biosynthesis. In

this regard, if Gb₃, like its adamantyl derivative (114) is an ABCB1 inhibitor, this would provide a feedback regulation of GSL synthesis which would serve to amplify relative Gb₃ levels.

Nascent ABC transporters destined for different subcellular compartments (e.g. ABCB10 to mitochondria, ABCA3 to lysosomes) are made in the ER and could function as GlcCer flippases during their glycosylation and anterograde transit through the Golgi. This suggests additional regulatory mechanisms may exist during this transit. We have found statins (which inhibit HMG Co-A reductase to reduce cholesterol synthesis and protein prenylation) markedly increase cellular GlcCer and Lc₃ synthesis and alter Golgi GCS distribution (115). Many ABC transporters have been found to bind cholesterol (116) and several are involved in its transport (117,118). Cholesterol-binding motifs are found in several ABC transporters, including ABCB1 (119). Cholesterol and GSLs accumulate in membrane lipid rafts (120) which contain ABC transporters (121). The cholesterol/GSL complex results in a GSL carbohydrate conformational change from membrane perpendicular to parallel (122), which masks the carbohydrate from ligand binding (123). Since there is a membrane cholesterol gradient from the ER to the TGN (124), this increase in concentration may differentially affect the relative sugar conformation of GlcCer, in addition to the energy barrier for membrane translocation within different Golgi regions, which may effect differential ABC transporter usage. ABC transporter cholesterol redistribution could in addition, play a role in GSL biosynthetic control.

Metabolic channeling in GSL biosynthesis provides an opportunity for the regulation of an individual GSL or GSL subsets, rather than the total ablation of GSL synthesis which results from the current use of inhibitors of GlcCer synthase (125,126). Other ABC transporters and possibly ATPases could be potential flippases and should be further investigated. The final proof of ABC transporter GlcCer flippase function must await membrane reconstitution of each recombinant transporter. Nevertheless, our discovery that multiple ABC transporters differentially control GSL biosynthesis provides potential targets for drug therapy to regulate specific GSL species or subsets in select cells/organs, and thereby more precisely ameliorate pathology in GSL dysregulated diseases.

Data availability: The raw mass spectrometric data has been deposited in MassIVE. To view dataset's webpage go to <https://doi.org/doi:10.25345/C5RN31>, Username: MSV000086365_reviewer, Password: LingwoodLab. To view dataset's files, go to <ftp://massive.ucsd.edu/MSV000086365/>, Username: MSV000086365, Password: LingwoodLab. All remaining data are contained within the article.

Acknowledgements

We would like to thank [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

References

1. Lingwood, C. A. (2011) Glycosphingolipid functions. *Cold Spring Harbor Perspectives in Biology* **3**, 1-26
2. D'Angelo, G., Capasso, S., Sticco, L., and Russo, D. (2013) Glycosphingolipids: synthesis and functions. *FEBS J* **280**, 6338-6353
3. Marques, A. R. A., and Saftig, P. (2019) Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases. *J Cell Sci* **132**
4. Langeveld, M., and Aerts, J. M. (2009) Glycosphingolipids and insulin resistance. *Progress in lipid research* **48**, 196-205
5. Chatterjee, S., Bedja, D., Mishra, S., Amuzie, C., Avolio, A., Kass, D. A., Berkowitz, D., and Renahan, M. (2014) Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E^{-/-} mice and rabbits fed a high-fat and -cholesterol diet. *Circulation* **129**, 2403-2413

6. McDonald, G., Deepak, S., Miguel, L., Hall, C. J., Isenberg, D. A., Magee, A. I., Butters, T., and Jury, E. C. (2014) Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. *The Journal of clinical investigation* **124**, 712-724
7. Karman, J., Tedstone, J. L., Gumlaw, N. K., Zhu, Y., Yew, N., Siegel, C., Guo, S., Siwkowski, A., Ruzek, M., Jiang, C., and Cheng, S. H. (2010) Reducing glycosphingolipid biosynthesis in airway cells partially ameliorates disease manifestations in a mouse model of asthma. *Int Immunol* **22**, 593-603
8. Prinetti, A., Prioni, S., Loberto, N., Aureli, M., Nocco, V., Illuzzi, G., Mauri, L., Valsecchi, M., Chigorno, V., and Sonnino, S. (2011) Aberrant glycosphingolipid expression and membrane organization in tumor cells: consequences on tumor-host interactions. *Adv Exp Med Biol* **705**, 643-667
9. Ho, M. Y., Yu, A. L., and Yu, J. (2017) Glycosphingolipid dynamics in human embryonic stem cell and cancer: their characterization and biomedical implications. *Glycoconj J* **34**, 765-777
10. Uddin, M. B., Roy, K. R., Hosain, S. B., Khiste, S. K., Hill, R. A., Jois, S. D., Zhao, Y., Tackett, A. J., and Liu, Y. Y. (2019) An N(6)-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. *Biochemical pharmacology* **160**, 134-145
11. Liu, Y. Y., Patwardhan, G. A., Xie, P., Gu, X., Giuliano, A. E., and Cabot, M. C. (2011) Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma. *International Journal of Oncology* **39**, 425-431
12. Gouaze-Andersson, V., and Cabot, M. C. (2011) Sphingolipid metabolism and drug resistance in hematological malignancies. *Anti-cancer agents in medicinal chemistry* **11**, 891-903
13. Chatterjee, S., Zheng, L., Ma, S., Bedja, D., Bandaru, V. V. R., Kim, G., Rangecroft, A. B., Iocco, D., and Campbell, S. A. (2020) Management of metabolic syndrome and reduction in body weight in type II diabetic mice by inhibiting glycosphingolipid synthesis. *Biochem Biophys Res Commun* **525**, 455-461

14. Bedja, D., Yan, W., Lad, V., Iocco, D., Sivakumar, N., Bandaru, V. V. R., and Chatterjee, S. (2018) Inhibition of glycosphingolipid synthesis reverses skin inflammation and hair loss in ApoE^{-/-} mice fed western diet. *Scientific reports* **8**, 11463
15. Henriques, A., Croixmarie, V., Priestman, D. A., Rosenbohm, A., Dirrig-Grosch, S., D'Ambra, E., Huebeker, M., Hussain, G., Boursier-Neyret, C., Echaniz-Laguna, A., Ludolph, A. C., Platt, F. M., Walther, B., Spedding, M., Loeffler, J. P., and Gonzalez De Aguilar, J. L. (2015) Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. *Human molecular genetics* **24**, 7390-7405
16. Taki, T. (2012) An approach to glycobiology from glycolipidomics: ganglioside molecular scanning in the brains of patients with Alzheimer's disease by TLC-blot/matrix assisted laser desorption/ionization-time of flight MS. *Biological & pharmaceutical bulletin* **35**, 1642-1647
17. Yahi, N., and Fantini, J. (2014) Deciphering the Glycolipid Code of Alzheimer's and Parkinson's Amyloid Proteins Allowed the Creation of a Universal Ganglioside-Binding Peptide. *PLoS ONE* **9**, e104751
18. Zhao, H., Przybylska, M., Wu, I. H., Zhang, J., Maniatis, P., Pacheco, J., Piepenhagen, P., Copeland, D., Arbeeny, C., Shayman, J. A., Aerts, J. M., Jiang, C., Cheng, S. H., and Yew, N. S. (2009) Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. *Hepatology* **50**, 85-93
19. Bietrix, F., Lombardo, E., van Roomen, C. P., Ottenhoff, R., Vos, M., Rensen, P. C., Verhoeven, A. J., Aerts, J. M., and Groen, A. K. (2010) Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor^{-/-} mice. *Arteriosclerosis, thrombosis, and vascular biology* **30**, 931-937
20. Pavlova, E. V., Archer, J., Wang, S., Dekker, N., Aerts, J. M., Karlsson, S., and Cox, T. M. (2015) Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. *The Journal of pathology* **235**, 113-124

21. Vitner, E. B., Achdout, H., Avraham, R., Politi, B., Cherry, L., Tamir, H., Yahalom-Ronen, Y., Paran, N., Melamed, S., Erez, N., and Israely, T. (2021) Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus. *The Journal of biological chemistry*, 100470
22. Wraith, J. E., Vecchio, D., Jacklin, E., Abel, L., Chadha-Boreham, H., Luzy, C., Giorgino, R., and Patterson, M. C. (2010) Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. *Molecular genetics and metabolism* **99**, 351-357
23. Shayman, J. A. (2018) Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease. *Seminars in nephrology* **38**, 183-192
24. Peterschmitt, M. J., Burke, A., Blankstein, L., Smith, S. E., Puga, A. C., Kramer, W. G., Harris, J. A., Mathews, D., and Bonate, P. L. (2011) Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. *Journal of clinical pharmacology* **51**, 695-705
25. Amiri, M., and Naim, H. Y. (2014) Long term differential consequences of miglustat therapy on intestinal disaccharidases. *J Inherit Metab Dis* **37**, 929-937
26. Giraldo, P., Andrade-Campos, M., Alfonso, P., Irun, P., Atutxa, K., Acedo, A., Barez, A., Blanes, M., Diaz-Morant, V., Fernández-Galán, M. A., Franco, R., Gil-Cortes, C., Giner, V., Ibañez, A., Latre, P., Loyola, I., Luño, E., Hernández-Martin, R., Medrano-Engay, B., Puerta, J., Roig, I., de la Serna, J., Salamero, O., Villalón, L., and Pocovi, M. (2018) Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. *Blood cells, molecules & diseases* **68**, 173-179
27. Peterschmitt, M. J., Cox, G. F., Ibrahim, J., MacDougall, J., Underhill, L. H., Patel, P., and Gaemers, S. J. M. (2018) A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration. *Blood cells, molecules & diseases* **68**, 185-191

28. Thibault, N., Ibrahim, J., Peterschmitt, M. J., Puga, A. C., Ross, L., Vu, L., Xue, Y., and Turpault, S. (2020) Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. *Molecular genetics and metabolism* **129**, 278-285
29. Coste, H., Martel, M. B., and Got, R. (1986) Topology of glucosylceramide synthesis in Golgi membranes from porcine submaxillary glands. *Biochimica et biophysica acta* **858**, 6-12
30. Futerman, A. H., and Pagano, R. E. (1991) Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. *Biochemical Journal* **280**, 295-302
31. Jeckel, D., Karrenbauer, A., Burger, K. N. J., Van Meer, G., and Wieland, F. (1992) Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. *Journal of Cell Biology* **117**, 259-267
32. Lannert, H., Bunning, C., Jeckel, D., and Wieland, F. T. (1994) Lactosylceramide is synthesized in the lumen of the Golgi apparatus. *FEBS Lett* **342**, 91-96
33. Lannert, H., Gorgas, K., Meißner, I., Wieland, F. T., and Jeckel, D. (1998) Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis. Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi. *Journal of Biological Chemistry* **273**, 2939-2946
34. Halter, D., Neumann, S., Van Dijk, S. M., Wolthoorn, J., De Mazière, A. M., Vieira, O. V., Mattjus, P., Klumperman, J., Van Meer, G., and Sprong, H. (2007) Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. *Journal of Cell Biology* **179**, 101-115
35. D'Angelo, G., Uemura, T., Chuang, C.-C., Polishchuk, E., Santoro, M., Ohvo-Rekila, H., Sato, T., Di Tullio, G., Varriale, A., D'Auria, S., Daniele, T., Capuani, F., Johannes, L., Mattjus, P., Monti, M., Pucci, P., Williams, R. L., Burke, J. E., Platt, F. M., Harada, A., and De Matteis, M. A. (2013) Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi. *Nature* **501**, 116-120

36. D'Angelo, G., Polishchuk, E., Tullio, G. D., Santoro, M., Campi, A. D., Godi, A., West, G., Bielawski, J., Chuang, C. C., Van Der Spoel, A. C., Platt, F. M., Hannun, Y. A., Polishchuk, R., Mattjus, P., and De Matteis, M. A. (2007) Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. *Nature* **449**, 62-67
37. Riordan, J. R., Deuchars, K., Kartner, N., Alon, N., Trent, J., and Ling, V. (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. *Nature* **316**, 817-819
38. Kim, Y., and Chen, J. (2018) Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. *Science* **359**, 915-919
39. Wang, Z., Chen, Y., Liang, H., Bender, A., Glen, R. C., and Yan, A. (2011) P-glycoprotein substrate models using support vector machines based on a comprehensive data set. *Journal of chemical information and modeling* **51**, 1447-1456
40. Romsicki, Y., and Sharom, F. J. (2001) Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. *Biochemistry* **40**, 6937-6947
41. Eckford, P. D. W., and Sharom, F. J. (2005) The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. *Biochemical Journal* **389**, 517-526
42. van Helvoort, A., Smith, A. J., Sprong, H., Fritzsche, I., Schinkel, A. H., Borst, P., and van Meer, G. (1996) MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine. *Cell* **87**, 507-517
43. Molinari, A., Cianfriglia, M., Meschini, S., Calcabrini, A., and Arancia, G. (1994) P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. *International Journal of Cancer* **59**, 789-795
44. Lala, P., Ito, S., and Lingwood, C. A. (2000) Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 105- to 106- fold increased cell sensitivity to verocytotoxin. Role of P-glycoprotein in glycolipid synthesis. *Journal of Biological Chemistry* **275**, 6246-6251

45. Eckford, P. D., and Sharom, F. J. (2006) P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. *Biochemistry and cell biology = Biochimie et biologie cellulaire* **84**, 1022-1033
46. De Rosa, M. F., Sillence, D., Ackerley, C., and Lingwood, C. (2004) Role of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis. *Journal of Biological Chemistry* **279**, 7867-7876
47. Wegner, M. S., Gruber, L., Mattjus, P., Geisslinger, G., and Grosch, S. (2018) The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1). *BMC cancer* **18**, 153
48. Tanaka, K., Kiguchi, K., Mikami, M., Aoki, D., and Iwamori, M. (2019) Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells. *Human cell* **32**, 447-452
49. Gouaze, V., Liu, Y. Y., Prickett, C. S., Yu, J. Y., Giuliano, A. E., and Cabot, M. C. (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. *Cancer Res* **65**, 3861-3867
50. Zhang, X., Wu, X., Li, J., Sun, Y., Gao, P., Zhang, C., Zhang, H., and Zhou, G. (2011) MDR1 (multidrug resistance 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. *Journal of surgical oncology* **104**, 466-471
51. Salustiano, E. J., da Costa, K. M., Freire-de-Lima, L., Mendonça-Previato, L., and Previato, J. O. (2020) Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias. *The Journal of biological chemistry* **295**, 6457-6471
52. Neumann, J., Rose-Sperling, D., and Hellmich, U. A. (2017) Diverse relations between ABC transporters and lipids: An overview. *Biochimica et biophysica acta. Biomembranes* **1859**, 605-618

53. Roland, B. P., Naito, T., Best, J. T., Arnaiz-Yepez, C., Takatsu, H., Yu, R. J., Shin, H. W., and Graham, T. R. (2018) Yeast and human P4-ATPases transport glycosphingolipids using conserved structural motifs. *The Journal of biological chemistry*
54. Akiyama, M. (2014) The roles of ABCA12 in epidermal lipid barrier formation and keratinocyte differentiation. *Biochimica et biophysica acta* **1841**, 435-440
55. Raggars, R. J., van Helvoort, A., Evers, R., and van Meer, G. (1999) The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. *J Cell Sci* **112 (Pt 3)**, 415-422
56. Mitsutake, S., Suzuki, C., Akiyama, M., Tsuji, K., Yanagi, T., Shimizu, H., and Igarashi, Y. (2010) ABCA12 dysfunction causes a disorder in glucosylceramide accumulation during keratinocyte differentiation. *Journal of dermatological science* **60**, 128-129
57. Sakai, K., Akiyama, M., Sugiyama-Nakagiri, Y., McMillan, J. R., Sawamura, D., and Shimizu, H. (2007) Localization of ABCA12 from Golgi apparatus to lamellar granules in human upper epidermal keratinocytes. *Experimental dermatology* **16**, 920-926
58. Hlavac, V., Brynychova, V., Vaclavikova, R., Ehrlichova, M., Vrana, D., Pecha, V., Kozevnikovova, R., Trnkova, M., Gatek, J., Kopperova, D., Gut, I., and Soucek, P. (2013) The expression profile of ATP-binding cassette transporter genes in breast carcinoma. *Pharmacogenomics* **14**, 515-529
59. Yanagi, T., Akiyama, M., Nishihara, H., Ishikawa, J., Sakai, K., Miyamura, Y., Naoe, A., Kitahara, T., Tanaka, S., and Shimizu, H. (2010) Self-improvement of keratinocyte differentiation defects during skin maturation in ABCA12-deficient harlequin ichthyosis model mice. *The American journal of pathology* **177**, 106-118
60. Hicks, A. A., Pramstaller, P. P., Johansson, A., Vitart, V., Rudan, I., Ugocsai, P., Aulchenko, Y., Franklin, C. S., Liebisch, G., Erdmann, J., Jonasson, I., Zorkoltseva, I. V., Pattaro, C., Hayward, C., Isaacs, A., Hengstenberg, C., Campbell, S., Gnewuch, C., Janssens, A. C., Kirichenko, A. V., Konig, I. R., Marroni, F., Polasek, O., Demirkan, A., Kolcic, I., Schwienbacher, C., Igl, W.,

- Biloglav, Z., Witteman, J. C., Pichler, I., Zaboli, G., Axenovich, T. I., Peters, A., Schreiber, S., Wichmann, H. E., Schunkert, H., Hastie, N., Oostra, B. A., Wild, S. H., Meitinger, T., Gyllenstein, U., van Duijn, C. M., Wilson, J. F., Wright, A., Schmitz, G., and Campbell, H. (2009) Genetic determinants of circulating sphingolipid concentrations in European populations. *PLoS Genet* **5**, e1000672
61. Budani, M., Mylvaganam, M., Binnington, B., and Lingwood, C. (2016) Synthesis of a novel photoactivatable glucosylceramide cross-linker. *J Lipid Res* **57**, 1728-1736
62. Nesvizhskii, A. I., Keller, A., Kolker, E., and Aebersold, R. (2003) A statistical model for identifying proteins by tandem mass spectrometry. *Analytical chemistry* **75**, 4646-4658
63. Boutin, M., Menkovic, I., Martineau, T., Vaillancourt-Lavigueur, V., Toupin, A., and Auray-Blais, C. (2017) Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients. *Analytical chemistry* **89**, 13382-13390
64. Amado, M., Almeida, R., Carneiro, F., Levery, S. B., Holmes, E. H., Nomoto, M., Hollingsworth, M. A., Hassan, H., Schwientek, T., Nielsen, P. A., Bennett, E. P., and Clausen, H. (1998) A family of human beta3-galactosyltransferases. Characterization of four members of a UDP-galactose:beta-N-acetyl-glucosamine/beta-nacetyl-galactosamine beta-1,3-galactosyltransferase family. *The Journal of biological chemistry* **273**, 12770-12778
65. Zhai, X., Momsen, W. E., Malakhov, D. A., Boldyrev, I. A., Momsen, M. M., Molotkovsky, J. G., Brockman, H. L., and Brown, R. E. (2013) GLTP-fold interaction with planar phosphatidylcholine surfaces is synergistically stimulated by phosphatidic acid and phosphatidylethanolamine. *J Lipid Res* **54**, 1103-1113
66. Rao, C. S., Chung, T., Pike, H. M., and Brown, R. E. (2005) Glycolipid transfer protein interaction with bilayer vesicles: modulation by changing lipid composition. *Biophys J* **89**, 4017-4028

67. Malinina, L., Malakhova, M. L., Kanack, A. T., Lu, M., Abagyan, R., Brown, R. E., and Patel, D. J. (2006) The liganding of glycolipid transfer protein is controlled by glycolipid acyl structure. *PLoS biology* **4**, e362
68. Sharom, F. J., Lugo, M. R., and Eckford, P. D. (2005) New insights into the drug binding, transport and lipid flippase activities of the p-glycoprotein multidrug transporter. *Journal of bioenergetics and biomembranes* **37**, 481-487
69. Khakhina, S., Johnson, S. S., Manoharlal, R., Russo, S. B., Blugeon, C., Lemoine, S., Sunshine, A. B., Dunham, M. J., Cowart, L. A., Devaux, F., and Moye-Rowley, W. S. (2015) Control of Plasma Membrane Permeability by ABC Transporters. *Eukaryotic cell* **14**, 442-453
70. Fitzgerald, M. L., Xavier, R., Haley, K. J., Welti, R., Goss, J. L., Brown, C. E., Zhuang, D. Z., Bell, S. A., Lu, N., McKee, M., Seed, B., and Freeman, M. W. (2007) ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. *J Lipid Res* **48**, 621-632
71. Wambach, J. A., Yang, P., Wegner, D. J., Heins, H. B., Kaliberova, L. N., Kaliberov, S. A., Curiel, D. T., White, F. V., Hamvas, A., Hackett, B. P., and Cole, F. S. (2016) Functional Characterization of ATP-Binding Cassette Transporter A3 Mutations from Infants with Respiratory Distress Syndrome. *American journal of respiratory cell and molecular biology* **55**, 716-721
72. Chai, A. B., Ammit, A. J., and Gelissen, I. C. (2017) Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation. *Respiratory research* **18**, 41
73. Childs, R. A., Wright, J. R., Ross, G. F., Yuen, C. T., Lawson, A. M., Chai, W., Drickamer, K., and Feizi, T. (1992) Specificity of lung surfactant protein SP-A for both the carbohydrate and the lipid moieties of certain neutral glycolipids. *The Journal of biological chemistry* **267**, 9972-9979
74. Srivastava, A. (2014) Progressive familial intrahepatic cholestasis. *Journal of clinical and experimental hepatology* **4**, 25-36

75. Chin, J. E., Soffir, R., Noonan, K. E., Choi, K., and Roninson, I. B. (1989) Structure and expression of the human MDR (P-glycoprotein) gene family. *Molecular and Cellular Biology* **9**, 3808-3820
76. Callen, D. F., Baker, E., Simmers, R. N., Seshadri, R., and Roninson, I. B. (1987) Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. *Human genetics* **77**, 142-144
77. Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., and Colotti, G. (2017) Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. *Drug Resistance Updates* **32**, 23-46
78. Smith, A. J., van Helvoort, A., van Meer, G., Szabo, K., Welker, E., Szakacs, G., Varadi, A., Sarkadi, B., and Borst, P. (2000) MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. *The Journal of biological chemistry* **275**, 23530-23539
79. Huang, J. F., Wen, C. J., Zhao, G. Z., Dai, Y., Li, Y., Wu, L. X., and Zhou, H. H. (2018) Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. *Cancer chemotherapy and pharmacology* **82**, 199-210
80. Hochrath, K., Krawczyk, M., Goebel, R., Langhirt, M., Rathkolb, B., Micklich, K., Rozman, J., Horsch, M., Beckers, J., Klingenspor, M., Fuchs, H., Gailus-Durner, V., Wolf, E., Acalovschi, M., Volmer, D. A., Hrabě de Angelis, M., and Lammert, F. (2012) The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **26**, 5081-5091
81. Zhao, H., Przybylska, M., Wu, I. H., Zhang, J., Siegel, C., Komarnitsky, S., Yew, N. S., and Cheng, S. H. (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. *Diabetes* **56**, 1210-1218

82. Bayeva, M., Khechaduri, A., Wu, R., Burke, M. A., Wasserstrom, J. A., Singh, N., Liesa, M., Shirihai, O. S., Langer, N. B., Paw, B. H., and Ardehali, H. (2013) ATP-binding cassette B10 regulates early steps of heme synthesis. *Circulation research* **113**, 279-287
83. Liesa, M., Luptak, I., Qin, F., Hyde, B. B., Sahin, E., Siwik, D. A., Zhu, Z., Pimentel, D. R., Xu, X. J., Ruderman, N. B., Huffman, K. D., Doctrow, S. R., Richey, L., Colucci, W. S., and Shirihai, O. S. (2011) Mitochondrial transporter ATP binding cassette mitochondrial erythroid is a novel gene required for cardiac recovery after ischemia/reperfusion. *Circulation* **124**, 806-813
84. Liesa, M., Qiu, W., and Shirihai, O. S. (2012) Mitochondrial ABC transporters function: the role of ABCB10 (ABC-me) as a novel player in cellular handling of reactive oxygen species. *Biochimica et biophysica acta* **1823**, 1945-1957
85. Shintre, C. A., Pike, A. C., Li, Q., Kim, J. I., Barr, A. J., Goubin, S., Shrestha, L., Yang, J., Berridge, G., Ross, J., Stansfeld, P. J., Sansom, M. S., Edwards, A. M., Bountra, C., Marsden, B. D., von Delft, F., Bullock, A. N., Gileadi, O., Burgess-Brown, N. A., and Carpenter, E. P. (2013) Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. *Proc Natl Acad Sci U S A* **110**, 9710-9715
86. Morales, A., Colell, A., Mari, M., Garcia-Ruiz, C., and Fernandez-Checa, J. C. (2003) Glycosphingolipids and mitochondria: Role in apoptosis and disease. *Glycoconjugate Journal* **20**, 579-588
87. Sano, R., Annunziata, I., Patterson, A., Moshiach, S., Gomero, E., Opferman, J., Forte, M., and d'Azzo, A. (2009) GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. *Mol Cell* **36**, 500-511
88. Novgorodov, S. A., Riley, C. L., Yu, J., Keffler, J. A., Clarke, C. J., Van Laer, A. O., Baicu, C. F., Zile, M. R., and Gudz, T. I. (2016) Lactosylceramide contributes to mitochondrial dysfunction in diabetes. *J Lipid Res* **57**, 546-562

89. Sillence, D. J., Puri, V., Marks, D. L., Butters, T. D., Dwek, R. A., Pagano, R. E., and Platt, F. M. (2002) Glucosylceramide modulates membrane traffic along the endocytic pathway. *J Lipid Res* **43**, 1837-1845
90. Sillence, D. J., and Platt, F. M. (2004) Glycosphingolipids in endocytic membrane transport. *Seminars in cell & developmental biology* **15**, 409-416
91. Meivar-Levy, I., and Futerman, A. H. (1999) Up-regulation of neutral glycosphingolipid synthesis upon long term inhibition of ceramide synthesis by fumonisin B1. *The Journal of biological chemistry* **274**, 4607-4612
92. De Angelis, I., Frigge, G., Raimondi, F., Stamatii, A., Zucco, F., and Caloni, F. (2005) Absorption of fumonisin B1 and aminopentol on an in vitro model of intestinal epithelium; the role of P-glycoprotein. *Toxicol : official journal of the International Society on Toxinology* **45**, 285-291
93. Gautherot, J., Durand-Schneider, A. M., Delautier, D., Delaunay, J. L., Rada, A., Gabillet, J., Housset, C., Maurice, M., and Ait-Slimane, T. (2012) Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4. *The Journal of biological chemistry* **287**, 5070-5078
94. Veldman, R. J., Klappe, K., Hinrichs, J., Hummel, I., van der Schaaf, G., Sietsma, H., and Kok, J. W. (2002) Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **16**, 1111-1113
95. Sillence, D. J. (2007) New insights into glycosphingolipid functions--storage, lipid rafts, and translocators. *International review of cytology* **262**, 151-189
96. Kamani, M. A., Provencal, P., Boutin, M., Pacienza, N., Fan, X., Novak, A., Huang, T. C., Binnington, B., Au, B. C., Auray-Blais, C., Lingwood, C. A., and Medin, J. A. (2016)

- Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. *Future science OA* **2**, FSO147
97. Borst, P., Zelcer, N., and van Helvoort, A. (2000) ABC transporters in lipid transport. *Biochimica et biophysica acta* **1486**, 128-144
 98. Maccioni, H. J. (2007) Glycosylation of glycolipids in the Golgi complex. *J Neurochem* **103 Suppl 1**, 81-90
 99. Kiarash, A., Boyd, B., and Lingwood, C. A. (1994) Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. *Journal of Biological Chemistry* **269**, 11138-11146
 100. Watkins, E. B., Gao, H., Dennison, A. J., Chopin, N., Struth, B., Arnold, T., Florent, J. C., and Johannes, L. (2014) Carbohydrate conformation and lipid condensation in monolayers containing glycosphingolipid Gb3: influence of acyl chain structure. *Biophysical journal* **107**, 1146-1155
 101. Schubert, T., Sych, T., Madl, J., Xu, M., Omidvar, R., Patalag, L. J., Ries, A., Kettelhoit, K., Brandel, A., Mely, Y., Steinem, C., Werz, D. B., Thuenauer, R., and Römer, W. (2020) Differential recognition of lipid domains by two Gb3-binding lectins. *Scientific reports* **10**, 9752
 102. Miles, E. W., Rhee, S., and Davies, D. R. (1999) The molecular basis of substrate channeling. *The Journal of biological chemistry* **274**, 12193-12196
 103. Giraud, C. G., and Maccioni, H. J. (2003) Ganglioside glycosyltransferases organize in distinct multienzyme complexes in CHO-K1 cells. *The Journal of biological chemistry* **278**, 40262-40271
 104. Bieberich, E., MacKinnon, S., Silva, J., Li, D. D., Tencomnao, T., Irwin, L., Kapitonov, D., and Yu, R. K. (2002) Regulation of ganglioside biosynthesis by enzyme complex formation of glycosyltransferases. *Biochemistry* **41**, 11479-11487
 105. Giraud, C. G., Daniotti, J. L., and Maccioni, H. J. (2001) Physical and functional association of glycolipid N-acetyl-galactosaminyl and galactosyl transferases in the Golgi apparatus. *Proc Natl Acad Sci U S A* **98**, 1625-1630

106. Russo, D., Della Ragione, F., Rizzo, R., Sugiyama, E., Scalabri, F., Hori, K., Capasso, S., Sticco, L., Fioriniello, S., De Gregorio, R., Granata, I., Guarracino, M. R., Maglione, V., Johannes, L., Bellenchi, G. C., Hoshino, M., Setou, M., D'Esposito, M., Luini, A., and D'Angelo, G. (2018) Glycosphingolipid metabolic reprogramming drives neural differentiation. *The EMBO journal* **37**
107. Diwischek, F., Morschhauser, J., and Holzgrabe, U. (2009) Cerulenin analogues as inhibitors of efflux pumps in drug-resistant *Candida albicans*. *Archiv der Pharmazie* **342**, 150-164
108. Pohl, A., Lage, H., Muller, P., Pomorski, T., and Herrmann, A. (2002) Transport of phosphatidylserine via MDR1 (multidrug resistance 1)P-glycoprotein in a human gastric carcinoma cell line. *Biochem J* **365**, 259-268
109. Ban, N., Matsumura, Y., Sakai, H., Takanezawa, Y., Sasaki, M., Arai, H., and Inagaki, N. (2007) ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. *The Journal of biological chemistry* **282**, 9628-9634
110. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. *The Journal of biological chemistry* **278**, 39706-39710
111. Taub, M. E., Podila, L., Ely, D., and Almeida, I. (2005) Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. *Drug metabolism and disposition: the biological fate of chemicals* **33**, 1679-1687
112. Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., and Altman, R. B. (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). *Pharmacogenetics and genomics* **21**, 152-161
113. Oude Elferink, R. P., and Zadina, J. (2001) MDR1 P-glycoprotein transports endogenous opioid peptides. *Peptides* **22**, 2015-2020
114. De Rosa, M. F., Ackerley, C., Wang, B., Ito, S., Clarke, D. M., and Lingwood, C. (2008) Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. *Journal of Biological Chemistry* **283**, 4501-4511

115. Binnington, B., Nguyen, L., Kamani, M., Hossain, D., Marks, D. L., Budani, M., and Lingwood, C. A. (2016) Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling. *Glycobiology* **26**, 166-180
116. Kimura, Y., Kodan, A., Matsuo, M., and Ueda, K. (2007) Cholesterol fill-in model: mechanism for substrate recognition by ABC proteins. *Journal of bioenergetics and biomembranes* **39**, 447-452
117. Karasinska, J. M., Rinninger, F., Lutjohann, D., Ruddle, P., Franciosi, S., Kruit, J. K., Singaraja, R. R., Hirsch-Reinshagen, V., Fan, J., Brunham, L. R., Bissada, N., Ramakrishnan, R., Wellington, C. L., Parks, J. S., and Hayden, M. R. (2009) Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **29**, 3579-3589
118. Clay, A. T., Lu, P., and Sharom, F. J. (2015) Interaction of the P-Glycoprotein Multidrug Transporter with Sterols. *Biochemistry* **54**, 6586-6597
119. Fantini, J., Di Scala, C., Evans, L. S., Williamson, P. T., and Barrantes, F. J. (2016) A mirror code for protein-cholesterol interactions in the two leaflets of biological membranes. *Scientific reports* **6**, 21907
120. Dietrich, C., Bagatolli, L. A., Volovyk, Z. N., Thompson, N. L., Levi, M., Jacobson, K., and Gratton, E. (2001) Lipid rafts reconstituted in model membranes. *Biophys J* **80**, 1417-1428
121. Klappe, K., Hummel, I., Hoekstra, D., and Kok, J. W. (2009) Lipid dependence of ABC transporter localization and function. *Chem Phys Lipids* **161**, 57-64
122. Lingwood, D., Binnington, B., Róg, T., Vattulainen, I., Grzybek, M., Coskun, Ü., Lingwood, C. A., and Simons, K. (2011) Cholesterol modulates glycolipid conformation and receptor activity. *Nature Chemical Biology* **7**, 260-262
123. Mahfoud, R., Manis, A., Binnington, B., Ackerley, C., and Lingwood, C. A. (2010) A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins. *Journal of Biological Chemistry* **285**, 36049-36059

124. Orci, L., Montesano, R., Meda, P., Malaisse-Lagae, F., Brown, D., Perrelet, A., and Vassalli, P. (1981) Heterogeneous distribution of filipin--cholesterol complexes across the cisternae of the Golgi apparatus. *Proc Natl Acad Sci U S A* **78**, 293-297
125. Platt, F. M., and Jeyakumar, M. (2008) Substrate reduction therapy. *Acta paediatrica (Oslo, Norway : 1992)* **97**, 88-93
126. Shayman, J. A., and Larsen, S. D. (2014) The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. *J Lipid Res* **55**, 1215-1225

Figure 1: DU-145 microsomal proteins cross-linked by GlcCer photoprobes.

XLA or XLB cross-linker preincubated \pm GLTP, were incubated with microsomes at 37°C for 1 h in the dark before cross-linking with UV light for 15 min. After solubilization, samples were purified by streptavidin-coupled beads, denatured, digested, and analysed by mass spectrometry-based proteomics. The control sample (without cross-linker) was compared to **A**) XLA cross-linked microsomal proteins, **B**) XLA cross-linked GLTP, and GLTP delivered XLA cross-linked microsomal proteins, **C**) XLB cross-linked microsomal proteins, and **D**) XLB cross-linked GLTP, and GLTP delivered XLB cross-linked microsomal proteins. Three candidate flippases were identified, ABCA3, ABCB4 and ABCB10, along with β -1,3-galactosyltransferase 1 (B3GALT1), when XLB was delivered to microsomes by GLTP. **E**) Networks between ABCB1, ABCA12, glycosyltransferases and identified proteins were compared using GeneMANIA (www.genemania.org). Co-expression (- - -) link two genes when expression levels are similar under different conditions. Predicted functional relationships between genes are indicated ($\square\square\square$). Co-localization ($\square - \square -$) link genes that are both expressed in the same tissue or in the same cellular location. Genetic interactions ($\square \square -$) link genes in which perturbation of one gene is modified by perturbation of the second gene. B3GALT1 has genetic interactions with ABCB1 and ABCB4. ABCB4 shows a predicted functional relationship with ABCB1, and is co-expressed with ST3GAL5 (β -galactoside α -2,3-sialyltransferase 5, GM₃ synthase), B4GALT6 (β -1,4-galactosyltransferase 6, LacCer synthase) and ABCB1.

Figure 2: GCS knockdown reduced all GSLs.

To estimate the maximum GSL depletion that could be achieved, GCS was depleted by siRNA in DU-145 cells. Total GSLs were examined post transfection, **A**) representative image of GCS knockdown confirmed by RT-PCR with GSC primers (55°C annealing temperature, 25 cycles), **B**) representative image of GSLs extracted and analysed by TLC stained with orcinol, **C**) scatter plot of quantified TLCs

shows all GSLs are reduced (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for LacCer, ■ for Gb₃, ▲ for Gb₄, and ▼ for GM₃. DU-145 cells were metabolically labeled with ¹⁴C-galactose for 5 hours post transfection, **D**) representative image of GCS RNA transcript knockdown confirmed by RT-PCR (55°C annealing temperature, 30 cycles), **E**) GSLs were extracted and newly synthesized GSLs were analyzed by TLC autoradiography (representative image), **F**) scatter plot of quantified TLCs shows all GSLs are reduced, significantly more than total GSLs stained with orcinol (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃.

Figure 3: ABCA3 knockdown reduced complex GSLs but increased LacCer.

ABCA3 was depleted by siRNA in DU-145 cells, and the effect on GSL biosynthesis examined post transfection, **A**) ABCA3 RNA transcript reduction was confirmed by RT-PCR using ABCA3 primers with annealing temperature of 57°C and 30 cycles (representative image shown), **B**) GSLs were extracted and analyzed by TLC stained with orcinol (representative TLC plate), **C**) scatter plot of quantified TLCs shows LacCer is increased and complex GSLs are reduced (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃. Cells were metabolically labeled with ¹⁴C-galactose for 5 hours post transfection, **D**) knockdown was confirmed by RT-PCR using ABCA3 primers with annealing temperature of 57°C and 30 cycles (representative image), **E**) GSLs were extracted and newly synthesized GSLs were analyzed by TLC autoradiography (representative TLC plate), **F**) scatter plot of quantified TLCs show complex GSLs were reduced but LacCer was increased (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃.

Figure 4: ABCB4 knockdown preferentially reduced neutral GSLs.

ABCB4 was depleted by siRNA in DU-145 cells and the effect on GSL biosynthesis examined post transfection, **A)** knockdown of ABCB4 RNA transcript was confirmed by RT-PCR using ABCB4 primers with an annealing temperature of 57°C and 35 cycles (representative image), **B)** GSLs were extracted and analyzed by TLC stained with orcinol (representative TLC plate), **C)** scatter plot of quantified GSLs shows neutral GSLs were preferentially reduced (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃. Cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection, **D)** knockdown was confirmed by RT-PCR using ABCB4 primers with an annealing temperature of 57°C and 35 cycles (representative image), **E)** GSLs were extracted and analyzed by TLC autoradiography (representative TLC plate), **F)** scatter plot of quantified TLCs shows neutral GSLs were preferentially reduced (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃.

Figure 5: ABCB10 knockdown reduced all GSLs.

ABCB10 was depleted by siRNA in DU-145 cells and the effect on GSL metabolism examined post transfection, **A)** RT-PCR (ABCB10 primers with an annealing temperature of 57°C and 35 cycles) shows ABCB10 RNA transcript was reduced by knockdown (representative image), **B)** GSLs were extracted and analyzed by TLC stained with orcinol (representative TLC plate), **C)** scatter plot of quantified TLCs show GSLs are slightly reduced except for Gb₃ (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃. Cells were metabolically labeled with ¹⁴C-

galactose for 5 h post transfection, **D**) knockdown was confirmed by RT-PCR with ABCB10 primers with an annealing temperature of 57°C and 30 cycles (representative image), **E**) GSLs were extracted and newly synthesized GSLs were analyzed by TLC autoradiography (representative TLC plate), **F**) scatter plot of quantified TLCs show all GSLs were reduced (least for Gb₃) (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃.

Figure 6: ABCA12 knockdown reduced all *de novo* GSL biosynthesis but neutral GSLs were preferentially affected.

ABCA12 was depleted by siRNA in DU-145 cells to determine if ABCA12 is involved in GSL biosynthesis. Total GSLs were examined post transfection, **A**) knockdown was confirmed by RT-PCR using ABCA12 primers with an annealing temperature of 55°C and 40 cycles (representative image), **B**) GSLs were extracted and analyzed by TLC stained with orcinol (representative TLC plate), **C**) scatter plot of quantified TLCs shows only LacCer is reduced (n = 3, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for LacCer, ■ for Gb₃, ▲ for Gb₄, and ▼ for GM₃. Cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection, **D**) RT-PCR (ABCA12 primers with an annealing temperature of 55°C and 37 cycles) was used to confirm ABCA12 RNA transcript depletion (representative image), **E**) GSLs were extracted and newly synthesized GSLs were analyzed by TLC autoradiography (representative TLC plate), **F**) scatter plot of quantified TLCs shows all GSLs were reduced with a preference for neutral GSLs (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃.

Figure 7: ABCB1 knockdown preferentially reduced gangliosides but increased Gb₃.

ABCB1 was depleted by siRNA in DU-145 cells, to clarify ABCB1 involvement in GSL biosynthesis. Total GSLs were examined post transfection, **A**) knockdown was confirmed by RT-PCR using ABCB1 primers with an annealing temperature of 60°C and 40 cycles (representative image), **B**) GSLs were extracted and analyzed by TLC stained with orcinol (representative TLC plate), **C**) scatter plot of quantified TLCs shows all GSLs are reduced (n = 3, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for LacCer, ■ for Gb₃, ▲ for Gb₄, and ▼ for GM₃. Cells were metabolically labeled with ¹⁴C-galactose for 5 h post transfection, **D**) RT-PCR (ABCB1 primers with an annealing temperature of 60°C and 40 cycles) shows knockdown effectively reduced ABCB1 mRNA transcript (representative image), **E**) extracted GSLs were analyzed by TLC autoradiography (representative TLC plate), **F**) scatter plot of quantified TLCs shows GM₃ was preferentially reduced but Gb₃ was increased (n = 2, in duplicate). Mean percent change represented as blue lines, standard error of mean represented as black solid lines, and each data point signified as ● for GlcCer, ■ for LacCer, ▲ for Gb₃, ▼ for Gb₄, and ◆ for GM₃.

Figure 8: Schematic of GSL synthesis and metabolic channeling in DU-145 cells.

GlcCer synthesized on the cytosolic leaflet of the Golgi (mainly *cis/medial*-Golgi) can follow two pathways, a FAPP2-independent vesicular pathway or a FAPP2-dependent non-vesicular pathway (upper panel). For ganglioside GSL synthesis, GlcCer can be translocated by Golgi-selective flippases to the lumen and transported through the Golgi cisternae and TGN via vesicular transport. For neutral GSL synthesis GlcCer is transported to the TGN by FAPP2, where it is translocated to the lumen by TGN-selective flippases. The grey arrow in the upper panel shows the direction of vesicular transport. The divergent effects of ABC depletion in DU-145 cells on select GSLs show complex GSLs are synthesized in a step-wise fashion from separate pools of GlcCer (lower panel). ABCB10 knockdown results in the


loss of both neutral GSLs and gangliosides. Therefore, GlcCer flipped by this transporter must be available for both ganglioside and globo-series GSL synthesis. Depletion of ABCA3 reduced all GSLs except LacCer was increased. Thus, ABCA3 counteracts the metabolic channeling (represented by red text and cylindrical channel) of a GlcCer, and subsequent LacCer, pool which is unavailable to Gb₃ or GM₃ synthase. Knockdown of ABCB1 reduced all GSLs (preferentially GM₃) except Gb₃ was increased. Therefore, ABCB1 is a Golgi-selective GlcCer flippase involved in GM₃ synthesis but not Gb₃ synthesis (represented by decreased opacity), and counteracts a GlcCer/LacCer channeled source for the synthesis of Gb₃ (represented by red text and cylindrical channel) unavailable to Gb₄ synthase. ABCB4 and ABCA12 knockdowns preferentially reduced globo-series GSL levels. Thus, ABCB4 and ABCA12 are TGN-selective GlcCer flippases which provides metabolic channeling for globo-series GSL synthesis, by generating a GlcCer pool that is not available for GM₃ synthase (represented by decreased opacity).

CRediT author statement


██████████: Conceptualization, Methodology, Investigation, Formal analysis, Validation, Writing - Original Draft, Writing - Review & Editing, Visualization, Funding acquisition. ██████████: Investigation. ██████████: Conceptualization, Methodology, Resources, Writing - Review & Editing, Supervision, Funding acquisition.

A

No XL control XLA+microsomes

**B**


No XL control XLA+GLTP




XLA+GLTP+microsomes

C

No XL control XLB+microsomes

**D**

No XL control XLB+GLTP



XLB+GLTP+microsomes

E

Networks


— Physical Interactions


--- Co-expression


— Predicted


- - - Co-localization


- · - Genetic Interactions




















Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:



Click here to access/download

Supporting Information



- Supplemental Data.docx

